Why the study?
Chemotherapy-induced peripheral neuropathy is a persistent toxicity of common anticancer regimens, but a significant gap remains in its assessment in clinical trials that neuroimaging and molecular biomarkers could fill.
Novel neuroimaging and molecular biomarkers hold potential as surrogate endpoints for assessing chemotherapy-induced peripheral neuropathy in clinical trials.
Neuroimaging and biomarkers should not yet inform CIPN management; leaves open their value as surrogate endpoints in trials.
INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a potentially persistent late toxicity of most common anticancer regimens. There is still a huge lack in CIPN assessment in clinical trials; therefore, biomarkers, both neuroimagery and molecular, could fill this gap. AREAS COVERED: In this review the first applications of high-resolution ultrasound (HRUS), magnetic resonance imaging (MRI) are discussed; different molecular biomarkers first report in CIPN are also addressed, broadening the spectrum of potential molecular candidates beyond pharmacogenomics. EXPERT OPINION: At the present moment, neuroimaging and biomarkers are not yet part of the clinical practice for CIPN management, but they deserved to be tested since they could be a valuable surrogate endpoint in a clinical trial. To ascertain the appropriateness of (a) potential biomarker(s), it is crucial to design a clinical trial based on sound design and taking advantage of international, multidisciplinary initiatives, such as the Toxic Neuropathy Consortium.
No takes yet. Share an insight, caveat, or question.
Paola Alberti (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: